Abstract:IMPORTANCE: Current methods for glioma treatment response assessment are limited. Intracranial cerebrospinal fluid (CSF) may provide a previously untapped source of longitudinal biomarkers, such as cell-free DNA (cfDNA), for disease monitoring. OBJECTIVE: To assess the feasibility of obtaining longitudinal intracranial CSF cfDNA from patients with gliomas during their disease course. DESIGN: This case series was initiated in 2021, with patients followed until last clinical follow-up (death or present time). SETTING: This single-center study was conducted at a large academic medical center. PARTICIPANTS: Adults with gliomas were recruited for longitudinal intracranial CSF collection using 1) Ommaya reservoirs, from which CSF would be sampled on at least two separate occasions, or 2) CSF collection from other clinically indicated CSF access devices, such as ventriculoperitoneal (VP) shunts. INTERVENTIONS: CSF was collected from Ommaya reservoirs in four patients and from an existing VP shunt in one patient. MAIN OUTCOMES AND MEASURES: The study aimed to collect CSF for biobanking and biomarker discovery, with the hypothesis that CSF could serve as a source of longitudinally acquirable biomarkers. RESULTS: Five patients (2 females, 3 males; median: 40 years, range 32-64 years) underwent longitudinal intracranial CSF collection via Ommaya reservoirs (n=4/5 patients) or VP shunt (n=1/5). Three patients had glioblastoma and two had astrocytoma, IDH-mutant, grade 4. In total, thirty-five CSF samples were obtained (median: 3.80 mL; 0.5-5 mL), with 30 (85.7%) yielding sufficient cfDNA for Next-Generation Sequencing (n=28) or Low-Pass Whole Genome sequencing (all samples). Tumor fraction was found to increase with radiographic progression. Changes in variant allelic frequencies (VAFs) may be seen within individual patients after resection and chemoradiation. In two patients, changes in tumor-specific IDH1 VAF correlated with CSF D-2-hydroxyglutarate levels, the oncometabolite of IDH mutant tumors. Copy number burden (CNB) decreased below the limit of quantification during treatment. CONCLUSIONS AND RELEVANCE: Longitudinal CSF cfDNA can feasibly be obtained via CSF access devices in patients with gliomas during their disease course. Ongoing studies will evaluate hypotheses generated in this case series regarding how longitudinal CSF cfDNA could be utilized to sensitively detect changes in disease burden. Trial Registration: [NCT04692324][1] https://clinicaltrials.gov/study/[NCT04692324][1]; [NCT04692337][2] https://clinicaltrials.gov/study/[NCT04692337][2]### Competing Interest StatementXiaoxi Dong, Chao Dai, Wei Mo, Pan Du, and Shidong Jia report employment at Predicine, Inc. Wei Mo, Pan Du, and Shidong Jia also report stock and other ownership interests in Predicine, Inc.### Clinical TrialNCT04692337### Funding StatementCRC was supported by the National Institute of Health T32GM145408. AMC was supported by NIH T32GM00868. TCB, TJK, SHK, and JEP were supported by NINDS R61 NS122096. TCB was supported by the Mayo Clinic Center for Individualized Medicine and CCaTS award UL1TR002377, the American Brain Tumor Association, Brains Together for the Cure, Humor to fight the Tumor, and Lucius & Terrie McKelvey. ### Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Mayo Clinic Institutional Review Board and all participants provided their consent to participate in this study. This study was performed in accordance with the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon request to the author. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT04692324&atom=%2Fmedrxiv%2Fearly%2F2024%2F02%2F24%2F2024.02.21.24303164.atom [2]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT04692337&atom=%2Fmedrxiv%2Fearly%2F2024%2F02%2F24%2F2024.02.21.24303164.atom

Abstract B041: Biomarkers of neurocognitive functioning: molecular signatures for cognitive outcomes in a cohort of primary brain tumor patients

Abstract A029: Use and predictors of perceived cognitive function using the Neuro-QoL perceived cognitive function scale in patients with primary brain tumors

Ncog-28. Serum Protein Biomarkers Linked To Neurodegenerative Processes Are Elevated In Glioma Patients And Associated With Severity Of Neurologic Symptoms

Abstract 7445: Association between C-reactive protein and cognitive impairment in IDH-mutant gliomas

Abstract 7453: Psychometric analysis of Neuro-QoL Perceived Cognitive Function tool in primary brain tumor patients

Abstract 7448: Serum IL-10 is associated with neurologic symptoms and interference in primary brain tumor patients

Abstract A030: The Montreal Cognitive Assessment (MoCA) administered virtually or via Duo APP in primary brain tumor patients: a preliminary analysis

Glioma Monitoring Via Longitudinal Intracranial Cerebrospinal Fluid Cell-Free DNA.

Abstract 6305: Evaluating clinical and sociodemographic risk for symptom-related functional interference in the primary brain tumor population

Abstract CT202: CSFctDNA as a surrogate for tumor tissue DNA in BC pts with CNS metastases: First results from the Brainstorm program (Oncodistinct 006)

Abstract 669: Immunophenotyping of Human Brain Tumors Reveals Myeloid Cell Mediated Anti-Glioma Axis

Tumor-related neurocognitive dysfunction in patients with diffuse glioma: a retrospective cohort study prior to antitumor treatment

Ncog-27. Higher Levels Of Serum Icam-1 And Il-10 Are Associated With Cognitive Dysfunction In Both Idh-Wildtype And Idh-Mutant Glioma

Abstract 4992: Baseline and alteration in pre vs post standard of care management serum-derived inflammatory markers are associated with radiation treatment volumes and patient outcomes in patients with GBM in a large-scale proteomic panel

Abstract 3703: Utility of circulating tumor DNA (ctDNA) from cerebrospinal fluid (CSF) for prognosis of patients with recurrent high grade glioma

Abstract 2294: Monitoring glioma treatment response through longitudinal analysis of cell-free DNA in cerebrospinal fluid: Insights from a comprehensive study using next-generation sequencing

Alzheimer disease-related biomarkers and cancer-related cognitive decline: the Thinking and Living with Cancer study

P01.03.B COGNITIVE REHABILITATION IN PRIMARY BRAIN CANCER: BASELINE PATIENT CHARACTERISTICS AND NEUROPSYCHOLOGICAL ASSESSMENTS

Abstract 3785: Clinical and genomic characterization of melanoma brain metastases

Abstract 6812: Durable control of brain tumors by glioma inhibitory macrophages and IL33

Serum Neurofilament Light, Glial Fibrillary Acidic Protein and Tau Are Possible Serum Biomarkers for Activity of Brain Metastases and Gliomas